The proposal, unveiled at the government's International Investment Summit today is headlined by the creation of a UK biotech ...

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

STAT reporters discuss investors' interest in autoimmune disease, GLP-1 supply issues, and big moments from #STATSummit.

The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...

Eli Lilly (NYSE: LLY) plans to invest $206M to expand its Suzhou, China site for Type 2 diabetes and obesity drugs. The ...

Investorideas , a global news source and expert investing resource, announces today's roundup of <a target=_blank href= ...

FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking ...

In that spirit, let's consider two biotech companies that could potentially deliver incredible returns next year: Recursion ...

Scholar Rock's surprising success. Apitegromab is an antibody that binds to another protein called myostatin, which normally ...

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.